medigraphic.com
ISSN 1817-5996 (Electronic)

2011, Number 17

<< Back Next >>

Rev Cub de Reu 2011; 13 (17)

Relación del intestino con la Espondilitis Anquilosante y otras espondiloartritis

Suárez MR, Martínez LJP, Molinero RC, Prada HD

Language: Spanish
References: 31
Page:
PDF size: 84.54 Kb.


ABSTRACT

No abstract.


REFERENCES

  1. Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, SturrockRD.Ankylosingspondylitis and HL-A 27. Lancet. 1973;1:904-7.

  2. Collantes Estévez E. El intestino en la patogenia de las espondiloartritis. Reumatol. Clin. 2007; 3 Supl 2: S29-32

  3. Ciccia F, et al. Overexpression of Interleukin-23, but Not Interleukin-17, as an Immunologic Signature of Subclinical Intestinal Inflammation in Ankylosing Spondylitis. Arthritis & Rhreumatims. 2009; 60 (4): 955-965.

  4. Plevy SE, Landers CJ, Prehn J, Carramanzana NM, Deem RL, Shealy D, et al. A role for TNFand mucosal T helper-1 cytokines in the pathogenesis of Crohn’s disease. J Immunol 1997; 159: 6276–82.

  5. Leirisalo-Repo M. Prognosis, course of disease, and treatment of thespondyloarthropathies. Rheumatic Dis Clin N Amer. 1998; 24: 737- 51.

  6. Rosenbaum JT, Davey MP. Time for a Gut Check: Evidence for the Hypothesis That HLA–B27 Predisposes to Ankylosing Spondylitis by Altering the Microbiome. Arthritis & Rheumatims. 2011; 63, (11): 3195– 3198.

  7. Rashid, T. Ebringer, A. Ankylosing spondylitis is linked to Klebsiella–– the evidence. Clin.Rheumatol. 2007; 26: 858–864.

  8. Hannu, T., inman, R., Granfors, K, Leirisalo-Repo, M. Reactive arthritis or post-infectious arthritis? Best Pract. Res. Clin. Rheumatol. 2006; 20: 419–433.

  9. Koehler L, Kuipers J.G, Zeigler H. Managing seronegative spondyloarthritides. Rheumatology. 2000; 39:360-368.

  10. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, et al. Type 1 T-helper cell predominance and interleukin- 12 expression in the gut of patients with Crohn’s disease. Am J Pathol 1997; 150: 823-832.

  11. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18: 263–6.

  12. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8: 345–50.

  13. Costa-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1 and 6 but not transforming growth factor are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8: 942–9.

  14. Mielants H, Veys EM, Cuvelier C, de Vos M. Ileocolonoscopic findings in seronegative spondylarthropathies. Br J Rheumatol 1988;27 Suppl 2:95– 105.

  15. Rudwaleitt M, Baeten D. Ankylosing spondylitis and bowel disease. Best Practice and Research Clin Rheeum. 2006; 3: 451-71.

  16. Ciccia F, Accardo-Palumbo A, Giardina A et al. Intestinal CD4 (+) CD25 (high) regulatory T cells are expanded in ankylosing spondylitis patients: a putative role for IL-10 in preventing intestinal TH17 response. Arthritis Rheum 2010; 62:3625-34.

  17. van Limbergen J, Wilson DC, Satsangi J. The genetics of Crohn’s disease. Ann Rev Genomics Hum Genet 2009; 10: 89-116.

  18. Acheson DWK, Luccioli S. Mucosal immune responses. Best Pr Res Cli Gast. 2004; 18: 387-404.

  19. Hill Gaston JS. Host-infectious agent interactions in the patogenesis of rheumatic disease. Cur Op Rheumatology2004; 16:371-3.

  20. Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: A review. Alt Med Rev. 2004; 9: 180-94.

  21. Smith JA, Marker-Herman E, Colbert RA. Pathogenesis of ankylosing spondylitis. Current concepts. Best Pract Res Clin Rheum. 2006; 3: 571- 91.

  22. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006;20: 451–71.

  23. YeremenkoN, Baeten D. IL-17 in spondyloarthritis: is the T-party over? .Arthritis Research & Therapy 2011, 13:115.

  24. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235–8.

  25. Di Meglio P, Di Cesare A, Laggner U, Chu CC, et al. The IL-23R R381Q gene variant protects against immune-mediated diseases by impairing IL- 23-induced Th17 effector response in humans. PLoS One 2011, 6:17160.

  26. Sarin R, Wu X, Abraham C: Infl ammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ and CD8+ human T cell functional responses. Proc Natl Acad Sci U S A2011, 108: 9560-9565.

  27. DeLay ML, Turner MJ, Klenk EI, Smith JA, Sowders DP, Colbert RA: HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum 2009, 60:2633-2643.

  28. Baeten D, Sieper J, Emery P, Braun J, et al The anti-IL17A monoclonal antibody secukinumab (AIN457) showed good safety and effi cacy in the treatment of active ankylosing spondylitis. Arthritis Rheum 2010, 62: 2840-2841.

  29. Khan M A. Ankylosing spondylitis and related spondyloarthropathies: the dramatic advances in the past decade Difficulties of diagnosis: how far has AS advanced? Rheumatology 2011; 50: 637-639.

  30. Hammer RE, Marka SD, Ricardson JA, et al. Spontaneous infllmatory disease in transgenic rats expressing HLA-B27 and humanbetha 2 microglulin: an animal model of HLA-B27-associated human disorders. Cell. 1990; 63:109-12.

  31. Sieper J, Braum J, Rutwaleit M, Boone A, Zink A. Ankylosing Spndylitis: an overview. Ann. Rheum. Diss. 2001; 61:367-11




2020     |     www.medigraphic.com